Zonulin Testing: What Serum and Stool Results Really Mean for “Leaky Gut”

Why people order a zonulin test

Zonulin blood and stool tests are marketed as ways to assess “leaky gut,” also known as increased intestinal permeability. The idea is appealing: a single marker that reflects how tightly the gut barrier is sealed. But what does a zonulin test actually measure, how accurate is it, and how should a result be interpreted alongside symptoms or diagnoses?

This focused review summarizes the science behind zonulin and tight junctions, what conventional medicine accepts versus what remains debated, how zonulin tests are performed, and their limits compared with functional permeability tests.

What is zonulin?

Zonulin is the human analogue of the bacterial toxin zonula occludens toxin and serves as a physiological modulator of intestinal tight junctions—the protein “rivets” (claudins, occludin, junctional adhesion molecules) that control what passes between intestinal epithelial cells. When zonulin signaling increases, tight junctions loosen, allowing more luminal contents (nutrients, water, antigens) to traverse the paracellular space. [Evidence: strong] (Fasano 2011, Physiological Reviews).

Zonulin has been identified as pre-haptoglobin 2, a precursor of the haptoglobin-2 protein, and engages receptors such as EGFR and PAR2 to regulate junctional dynamics. [Evidence: strong] (Tripathi et al. 2009, PNAS).

Conditions linked to zonulin and permeability

• Celiac disease: People with active celiac disease often show higher zonulin signaling and increased permeability, which tend to normalize on a gluten-free diet. Pharmacologic tight-junction modulators (e.g., larazotide acetate) have reduced symptoms in randomized trials, though mucosal healing outcomes are inconsistent. [Evidence: strong for association; moderate for symptom benefit with pharmacologic modulation] (Fasano 2011; systematic reviews of larazotide RCTs 2017–2022).
• Inflammatory bowel disease (IBD): Studies report altered permeability and elevated zonulin-related signals in subsets of IBD, but inflammation itself can confound results. [Evidence: moderate] (Camilleri 2019, Neurogastroenterology & Motility).
• Irritable bowel syndrome (IBS): Some small studies—particularly in diarrhea-predominant IBS—suggest increased permeability, yet findings are heterogeneous and methods vary. [Evidence: emerging] (Camilleri 2019).
• Metabolic conditions: Elevated zonulin-like signals have been observed with obesity and type 2 diabetes, correlating with markers of metabolic endotoxemia; causality is unresolved. [Evidence: emerging] (Camilleri 2019).

What does a zonulin test actually measure?

Commercial assays typically use enzyme-linked immunosorbent assay (ELISA) kits to quantify zonulin in serum or stool. However, multiple investigations have questioned whether some widely used kits detect true pre-haptoglobin 2 (zonulin) versus related “zonulin family peptides” or even unrelated proteins (e.g., complement C3). [Evidence: strong] (Scheffler et al. 2018, PLoS One).

Key implications:

• Different kits may measure different analytes. Two labs can report discordant values from the same sample. [Evidence: strong] (Scheffler 2018).
• Reported concentrations often show poor correlation with functional permeability tests (see below). [Evidence: moderate] (Camilleri 2019; Bischoff et al. 2014, United European Gastroenterology Journal).
• Fecal versus serum zonulin may reflect different processes (luminal shedding vs systemic signals). Neither is a validated standalone diagnostic for “leaky gut.” [Evidence: moderate] (Camilleri 2019).

Bottom line: Current commercial zonulin tests may not provide a specific, validated measure of the canonical zonulin protein or of whole-gut permeability. They are best interpreted cautiously and in context. [Evidence: strong]

Serum vs stool zonulin

• Serum/plasma: Intended to reflect circulating zonulin-family activity affecting systemic epithelial barriers (gut and possibly beyond). Variability between assay brands is a major limitation. [Evidence: strong] (Scheffler 2018).
• Stool: Intended to capture luminal or mucosal zonulin-family peptides. Fecal matrix effects and inflammation can influence results. Correlation with clinical disease activity and with serum values is inconsistent. [Evidence: moderate] (Camilleri 2019).

How zonulin compares with the lactulose–mannitol (L/M) test

The L/M test is a functional assessment in which two sugars are ingested; mannitol (small) is readily absorbed transcellularly, while lactulose (larger) should minimally traverse tight junctions. Their urinary excretion ratio over a set period approximates small-intestinal paracellular permeability. [Evidence: strong] (Bischoff et al. 2014).

Limitations of L/M:

• Influenced by gastric emptying, renal function, small-bowel length, and small intestinal bacterial overgrowth. [Evidence: moderate] (Bischoff 2014).
• Primarily reflects small-intestinal, not colonic, permeability. [Evidence: moderate] (Bischoff 2014).

Correlation between L/M ratios and commercial zonulin values is often weak, likely due to biological complexity and analytical variability. [Evidence: moderate] (Camilleri 2019).

Clinical take: Both measures are mainly used in research. Routine permeability testing—zonulin or L/M—is generally not recommended in conventional practice outside specific contexts (e.g., celiac research protocols). [Evidence: strong] (Camilleri 2019; Bischoff 2014).

What conventional medicine accepts vs what is debated

Accepted:

• The gut barrier is dynamic, and increased permeability occurs in defined conditions (e.g., active celiac disease, subsets of IBD, critical illness). [Evidence: strong]
• Permeability can change with diet, medications (e.g., NSAIDs), stress, infections, and inflammation. [Evidence: strong] (Bischoff 2014; Camilleri 2019).

Debated/uncertain:

• The diagnostic utility of a single biomarker (zonulin) to define “leaky gut” in otherwise healthy individuals. [Evidence: strong for uncertainty]
• The clinical value of commercial serum or stool zonulin testing in guiding treatment decisions. [Evidence: strong for uncertainty] (Scheffler 2018; Camilleri 2019).

If you already have a zonulin result

• High value: May reflect assay variability, intestinal inflammation, or a true increase in barrier modulation. On its own, it does not diagnose a disease or confirm “leaky gut.” Consider the broader clinical picture—symptoms, established diagnoses (e.g., celiac serology and biopsy, fecal calprotectin for bowel inflammation), diet, medications, and recent infections. [Evidence: strong for need to contextualize]
• Normal/low value: Does not exclude increased permeability, especially if symptoms are present or another test (e.g., L/M) is abnormal. [Evidence: moderate]

In both cases, results are best viewed as exploratory research-type data rather than definitive clinical endpoints. [Evidence: strong]

Can lifestyle or therapies “lower zonulin” and improve the barrier?

Research suggests some interventions may help aspects of barrier function, but zonulin-specific outcomes are inconsistently measured:

• Gluten-free diet in celiac disease improves permeability and symptoms; zonulin-related signaling often normalizes. [Evidence: strong] (Fasano 2011).
• Tight-junction modulators (e.g., larazotide acetate) reduce gluten-related symptoms in celiac trials, with mixed effects on histology. These agents remain investigational in many regions. [Evidence: moderate] (systematic reviews 2017–2022).
• Nutritional/phytochemical approaches: Small human trials suggest L-glutamine, zinc carnosine, and bovine colostrum may reduce exercise-, medication-, or stress-associated increases in permeability; effects on zonulin per se are less clear. [Evidence: emerging to moderate] (Bischoff 2014; systematic reviews of colostrum and mucosal protection 2014–2019).
• Probiotics: Meta-analyses indicate certain strains may support barrier function in specific contexts, though results vary by species/strain and population. [Evidence: moderate] (Camilleri 2019).

Traditional perspectives: In Traditional Chinese Medicine, patterns such as “Spleen Qi deficiency” emphasize digestive resilience and barrier-like functions; in Ayurveda, concepts of agni (digestive fire) and ama (metabolic residue) similarly highlight gut integrity. Soothing demulcents historically used for digestive comfort—such as slippery elm and aloe vera—and broths are traditional tools. Modern evidence for direct effects on validated permeability endpoints is limited. [Evidence: traditional/emerging]

Note: No single food, herb, or supplement has proven to normalize a zonulin test in a way that clearly predicts clinical outcomes across conditions. [Evidence: strong for uncertainty]

How to think about testing going forward

• Use established diagnostic pathways for known diseases (e.g., guideline-based testing for celiac disease, IBD). [Evidence: strong]
• If exploring permeability in research or specialized care, the L/M test provides a functional readout; zonulin assays remain methodologically heterogeneous. [Evidence: strong]
• Focus on modifiable fundamentals—balanced eating patterns, adequate sleep, stress management, and movement—that broadly support gut-immune health regardless of a single biomarker. [Evidence: moderate]

Bottom line

• Zonulin regulates tight junctions and is central to the biology of intestinal permeability. [Evidence: strong]
• Commercial zonulin tests (serum/stool) have significant analytical limitations; many do not specifically measure pre-haptoglobin 2 and correlate poorly with functional permeability tests. [Evidence: strong]
• Increased permeability is real in certain conditions (e.g., active celiac, subsets of IBD), but a standalone zonulin result does not diagnose “leaky gut” or direct treatment. [Evidence: strong]
• Research suggests diet, selected nutraceuticals, probiotics, and investigational drugs may influence barrier function in specific settings, but zonulin-targeted testing is not a routine clinical tool. [Evidence: moderate]
• Traditional digestive approaches may provide symptomatic support, yet modern, validated permeability outcomes remain understudied. [Evidence: traditional/emerging]

Consider zonulin testing as exploratory data at best. Interpreting results in context—with clinical evaluation and established diagnostics—remains the most reliable path.

References (selected): Fasano A. Physiological Reviews, 2011; Tripathi A et al. PNAS, 2009; Bischoff SC et al. United European Gastroenterology Journal, 2014; Camilleri M. Neurogastroenterology & Motility, 2019; Scheffler L et al. PLoS One, 2018; systematic reviews of larazotide acetate RCTs (2017–2022).